Form 4: Xeris Biopharma COO Exercises Stock Options
Insider Transaction Report
Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch exercised stock options, acquiring 48,898 shares of common stock.
Summary
- Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., reported transactions on March 12, 2026.
- McCulloch exercised stock options to acquire 48,894 shares of common stock at an exercise price of $4.09 per share.
- McCulloch also exercised stock options to acquire 4 shares of common stock at an exercise price of $3.94 per share.
- Following these transactions, McCulloch directly beneficially owns 1,777,725 shares of common stock.
- An additional 25,000 shares are indirectly beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal, as the exercise of options and continued beneficial ownership by a key executive like the COO suggests ongoing alignment with shareholder interests and potential confidence in the company's long-term value.
Positives
- The exercise of stock options by a key executive like the President and COO can signal confidence in the company's future prospects.
- The acquisition of common stock increases the executive's direct equity stake in the company, aligning interests with shareholders.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that routine insider option exercises, such as those reported by Kevin McCulloch, are common in the biopharma industry. They often reflect executives monetizing vested equity compensation rather than a direct signal about immediate operational performance or strategic shifts. The decision to exercise and hold shares can be interpreted as a long-term commitment to the company, aligning executive interests with shareholder value.
Comparison to Industry Standards
- This filing reports a standard insider transaction (exercise of stock options) which is a common form of executive compensation and wealth management across all industries, including biopharma. There are no specific company or project results to compare against industry benchmarks in this type of filing.
Related Party Transactions
- The filing notes 25,000 shares indirectly beneficially owned by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Stakeholder Impact
- Shareholders: May view the executive's increased direct ownership as a positive sign of alignment and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2020-08-26 | Date stock options were received under the 2018 Plan, with vesting over two years. |
| 2020-12-10 | Date stock options were received under the 2018 Plan, with vesting over two years. |
| 2026-03-12 | Date of stock option exercise transactions. |
| 2026-03-16 | Date the Form 4 was signed by Attorney-in-Fact. |
| 2027-12-10 | Expiration date for 48,894 stock options. |
| 2030-08-26 | Expiration date for 4 stock options. |
Keywords
Xeris Biopharma Holdings Inc., XERS, Kevin McCulloch, Insider Transaction, Stock Options, Beneficial Ownership, Form 4, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.